B cells from African American lupus patients exhibit an activated phenotype.

Autor: Menard LC; Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA., Habte S; Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA., Gonsiorek W; Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA., Lee D; Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA., Banas D; Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA., Holloway DA; Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA., Manjarrez-Orduno N; Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA., Cunningham M; Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA., Stetsko D; Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA., Casano F; Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA., Kansal S; Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA., Davis PM; Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA., Carman J; Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA., Zhang CK; Immunoscience Translational Bioinformatics, Bristol-Myers Squibb Company, Pennington, New Jersey, USA., Abidi F; Division of Rheumatology, Northwell Health, Great Neck, New York, USA., Furie R; Division of Rheumatology, Northwell Health, Great Neck, New York, USA., Nadler SG; Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA., Suchard SJ; Discovery Translational Sciences, Bristol-Myers Squibb Company, Princeton, New Jersey, USA.
Jazyk: angličtina
Zdroj: JCI insight [JCI Insight] 2016 Jun 16; Vol. 1 (9), pp. e87310. Date of Electronic Publication: 2016 Jun 16.
DOI: 10.1172/jci.insight.87310
Abstrakt: Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease driven by both innate and adaptive immune cells. African Americans tend to present with more severe disease at an earlier age compared with patients of European ancestry. In order to better understand the immunological differences between African American and European American patients, we analyzed the frequencies of B cell subsets and the expression of B cell activation markers from a total of 68 SLE patients and 69 normal healthy volunteers. We found that B cells expressing the activation markers CD86, CD80, PD1, and CD40L, as well as CD19 + CD27 - IgD - double-negative B cells, were enriched in African American patients vs. patients of European ancestry. In addition to increased expression of CD40L, surface levels of CD40 on B cells were lower, suggesting the engagement of the CD40 pathway. In vitro experiments confirmed that CD40L expressed by B cells could lead to CD40 activation and internalization on adjacent B cells. To conclude, these results indicate that, compared with European American patients, African American SLE patients present with a particularly active B cell component, possibly via the activation of the CD40/CD40L pathway. These data may help guide the development of novel therapies.
Databáze: MEDLINE
Externí odkaz: